ReviewWorld journal of gastrointestinal pathophysiology2025
Pathophysiology of depression and anxiety in metabolic dysfunction-associated steatotic liver disease.
Review in World journal of gastrointestinal pathophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inverse Association Between Dietary Niacin Intake and Prevalence of Depressive Symptoms in Adults With Metabolic-Associated Fatty Liver Disease: A Cross-Sectional Study.Food science & nutrition · 2026Article
- Neuroendocrine-immune perturbations in metabolic disease: pathophysiological mechanisms underlying cognitive impairment.Frontiers in human neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease with a continually rising global prevalence and significant mortality rates. Emerging evidence suggests a strong association between MASLD and mental health disorders such as depression and anxiety. In addition to the shared risk factors such as obesity, type 2 diabetes and insulin resistance which contribute to this relationship through mechanisms involving systemic inflammation and oxidative stress; other pathophysiological mechanisms such as dysregulation of hypothalamic-pituitary-adrenal axis, neurotransmitter imbalances and gut dysbiosis have also been proposed to play a significant role. The current paper aims to review the pathophysiological mechanisms underlying the association between MASLD and mood disorders such as depression and anxiety. We note a bidirectional relationship between these two disorders, and the dual burden of both these disease processes can be alleviated by early detection and encouraging a more proactive and holistic approach through diet and lifestyle changes. This review summarizes the existing literature on association between MASLD and depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.